Akums launches generic formulation to treat migraine Akums Drugs & Pharmaceuticals Ltd., a contract manufacturing pharmaceutical company, on Friday announced that it has launched the Lasmiditan tablet which is prescribed to treat migraine. This medication has received approvals from the Drug Controller General of India (DCGI) and the United States Food and Drug Administration (USFDA). It is the generic formulation of Eli Lilly’s REYVOW which is indicated for treatment of acute migraine. In a 2019 report, it was revealed that headache disorders, including both migraines and tension-type headaches, have emerged as the most prevalent neurological conditions in India, affecting an astonishing 488 million individuals. The International Headache Society (IHS) outlines criteria for diagnosing migraine, including specific characteristics and associated symptoms observed in at least five attacks. Two main subtypes, migraine without aura and migraine with aura, present distinct features, with the latter involving focal neurological symptoms preceding or accompanying the headache. “Migraine poses a significant global impact. According to a 2019 report, headache disorders, encompassing migraine and tension-type headaches, emerged as the most widespread neurological conditions in India, impacting a staggering 488 million individuals. Despite this substantial prevalence and the resulting disability, migraine awareness among patients remains inadequate. Compounded by frequent misdiagnosis as other headache disorders, these factors contribute to an increased burden associated with migraine. In light of this, Akums aims to provide a solution for managing this condition with the introduction of the Lasmiditan tablet,” Sanjeev Jain, Joint Managing Director, Akums Drugs & Pharmaceuticals Ltd., said.
Also Read: Zerodha’s Nikhil Kamath tells when to buy stocks, shares Buffett formula to find the right time
FII and DII trades: Foreign Institutional Investors (FII) have been net buyers of domestic stocks for successive days now. On Wednesday, FIIs pumped in Rs 2,347 crore. Domestic Institutional Investors (DII) have been net sellers, pulling out Rs 510 crore yesterday.
IPO watch: Syrma SGS Technology enters the final day of bidding today. So far the issue, that opened last week, has been subscribed 2.27 times. Retail investors have subscribed their portion 2.66 times while NIIs have bid for their quota 3.58 times and QIB portion has been bid for 0.71 times.
(The stock recommendations in this story are by the respective research analysts and brokerage firms. FinancialExpress.com does not bear any responsibility for their investment advice. Capital markets investments are subject to rules and regulations. Please consult your investment advisor before investing.)